Head-to-head evidence
LY3962681 vs UB-312
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
LY3962681
Developed by Prevail Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2030 · NCT06565195 (registry estimate)
UB-312
Developed by Vaxxinity
NCT04075318 · Phase 1 · completed
A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY3962681's landscape · UB-312's landscape